Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Emery, P
Gottenberg, J E
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martínez Taboada, V M
Barile-Fabris, L
Moots, R J
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Gylvin, L Hinsch
Finckh, Axel

Open link

Publication date

January 2015

DOI

10.1136/annrheumdis-2013-203993

Publisher

BMJ

ISSN

0003-4967

Citation count (estimate)

Abstract

To compare the effectiveness of rituximab versus an alternative tumour necrosis factor (TNF) inhibitor (TNFi) in patients with rheumatoid arthritis (RA) with an inadequate response to one previous TNFi

Extracted data

We use cookies to provide a better user experience.

Data Protection

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Emery, P
Gottenberg, J E
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martínez Taboada, V M
Barile-Fabris, L
Moots, R J
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Gylvin, L Hinsch
Finckh, Axel

Open link

Publication date

January 2015

DOI

10.1136/annrheumdis-2013-203993

Publisher

BMJ

ISSN

0003-4967

Citation count (estimate)

Abstract

Extracted data

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

of Rheumatic and

Musculoskeletal Medicine
Roth A
Et Al. Ann Rheum

January 2014

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to re...

Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study

Axel, Finckh
Jacques Eric, Gottenberg
Chiedzo, Mpofu
William, G. Bensen
Andrea, Rubbert Roth
Fedra, Irazoque
Victor, Mart\u131\u2019nez Taboada
Carol, Chung
Lykke, Hinsch Gylvin
Ferri, Clodoveo
Paul, Emery

January 2012

Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blocker...

Axel, Finckh
Jacques Eric, Gottenberg
Chiedzo, Mpofu
William, G. Bensen
Andrea, Rubbert Roth
Fedra, Irazoque
Victor, Martı’nez Taboada
Carol, Chung
Lykke, Hinsch Gylvin
Paul, Emery
FERRI, Clodoveo

January 2012

Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blocker...

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Emery, P
Gottenberg, JE
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martinez Taboada, VM
Barile-Fabris, L
Moots, RJ
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Hinsch Gylvin, L
Finckh, A

June 2015

OBJECTIVES: To compare the effectiveness of rituximab versus an alternative tumour necrosis factor (...

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh, Axel
Ciurea, A.
Brulhart, L.
Moller, B.
Walker, U. A.
Courvoisier, Delphine
Kyburz, D.
Dudler, J.
Gabay, Cem

January 2010

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, D
van Melckebeke, J
Dale, J
Messow, C
McConnachie, A
Walker, A
Munro, R
McLaren, J
McRorie, E
Packham, J
Buckley, C
Harvie, J
Taylor, P
Choy, E
Pitzalis, C
McInnes, I

January 2016

Background Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatm...

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Finckh, Axel
Ciurea, Adrian
Brulhart, Laure Sophie
Kyburz, Diego
Möller, Burkhard
Dehler, Silvia
Revaz, Sylvie
Dudler, Jean
Gabay, Cem
Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis

January 2007

Objective: Patients with rheumatoid arthritis (RA) in whom the response to anti-tumor necrosis facto...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

OBJECTIVE: To compare the effectiveness of a third tumor necrosis factor-alpha (TNF-alpha)-blocking ...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Axel, Finckh
Jacques Eric, Gottenberg
Chiedzo, Mpofu
William, G. Bensen
Andrea, Rubbert Roth
Fedra, Irazoque
Victor, Mart\u131\u2019nez Taboada
Carol, Chung
Lykke, Hinsch Gylvin
Ferri, Clodoveo
Paul, Emery

January 2012

Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blocker...

Axel, Finckh
Jacques Eric, Gottenberg
Chiedzo, Mpofu
William, G. Bensen
Andrea, Rubbert Roth
Fedra, Irazoque
Victor, Martı’nez Taboada
Carol, Chung
Lykke, Hinsch Gylvin
Paul, Emery
FERRI, Clodoveo

January 2012

Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blocker...

Emery, P
Gottenberg, JE
Rubbert-Roth, A
Sarzi-Puttini, P
Choquette, D
Martinez Taboada, VM
Barile-Fabris, L
Moots, RJ
Ostor, A
Andrianakos, A
Gemmen, E
Mpofu, C
Chung, C
Hinsch Gylvin, L
Finckh, A

June 2015

OBJECTIVES: To compare the effectiveness of rituximab versus an alternative tumour necrosis factor (...

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh, Axel
Ciurea, A.
Brulhart, L.
Moller, B.
Walker, U. A.
Courvoisier, Delphine
Kyburz, D.
Dudler, J.
Gabay, Cem

January 2010

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, D
van Melckebeke, J
Dale, J
Messow, C
McConnachie, A
Walker, A
Munro, R
McLaren, J
McRorie, E
Packham, J
Buckley, C
Harvie, J
Taylor, P
Choy, E
Pitzalis, C
McInnes, I

January 2016

Background Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatm...

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Finckh, Axel
Ciurea, Adrian
Brulhart, Laure Sophie
Kyburz, Diego
Möller, Burkhard
Dehler, Silvia
Revaz, Sylvie
Dudler, Jean
Gabay, Cem
Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis

January 2007

Objective: Patients with rheumatoid arthritis (RA) in whom the response to anti-tumor necrosis facto...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Effectiveness of a Third Tumor Necrosis Factor-alpha-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis

Blom, M.
Kievit, W.
Donders, A.R.T.
Broeder, A. den
Straten, V.H.
Kuper, I.
Visser, H.
Jansen, T.L.Th.A.
Brus, H.L.
Branten, A.J.W.
Laar, M.A. van der
Riel, P.L. van

January 2011

OBJECTIVE: To compare the effectiveness of a third tumor necrosis factor-alpha (TNF-alpha)-blocking ...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Abstract

Extracted data

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Abstract

Extracted data

Related items

Related items